search for


Treatment for Burning Mouth Syndrome: A Clinical Review
J Oral Med Pain 2023;48:11-15
Published online March 30, 2023;
© 2023 Korean Academy of Orofacial Pain and Oral Medicine

YoungJoo Shim

Department of Oral Medicine, Daejeon Dental Hospital, Institute of Wonkwang Dental Research, College of Dentistry, Wonkwang University, Daejeon, Korea
Correspondence to: YoungJoo Shim
Department of Oral Medicine, Daejeon Dental Hospital, Institute of Wonkwang Dental Research, College of Dentisry, Wonkwang University, 77 Dunsan-ro, Seogu, Daejeon 35233, Korea
Received January 5, 2023; Revised January 30, 2023; Accepted February 2, 2023.
This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Burning mouth syndrome (BMS) is a chronic idiopathic orofacial pain. BMS is currently classified as a neuropathic pain condition, but it is difficult to pinpoint the precise neuropathic mechanisms involved in each patient. It is challenging to complete the cure for BMS. Clinicians should treat BMS patients based on evidence. There is pharmacological and non-pharmacological therapy in the treatment modalities of BMS. The provision of objective information and reassurance as part of cognitive behavioral therapy is critical in the treatment of BMS. This paper will review the evidence-based treatment of BMS and discuss what we need to do.
Keywords : Burning mouth syndrome; Clonazepam; Cognitive behavioral therapy

The International Classification of Orofacial Pain (ICOP) categorizes burning mouth syndrome (BMS) as idiopathic orofacial pain and defines it as an intraoral burning or dysaesthetic sensation, recurring daily for more than 2 hours per day for more than 3 months, without evident causative lesions on clinical examination and investigation [1]. In ICOP, previously called primary BMS was defined as BMS. Burning sensation, xerostomia, and taste disturbance make up the triad of symptoms for BMS. BMS commonly affects the tongue, lip, palate, gums, and other oral mucosa. Anxiety, depression, and insomnia are frequent comorbid conditions [2]. BMS, formerly thought to be psychogenic pain, is now considered neuropathic pain. In clinical settings, determining the precise neuropathic mechanism in individuals is difficult. Furthermore, there are no global guidelines on BMS treatment and BMS has low spontaneous remission prevalence [3]. As a result, treating BMS is difficult.

Burning pain is caused by a variety of factors, and it is critical to identify these factors in each patient. Clinicians should try to find factors through diagnostic tools, and appropriate treatment should be provided according to the factors. BMS treatment should be evidence-based, with evidence-based on BMS pathogenesis, treatment meta-analysis, and predictors of treatment outcome reported in previous studies. This paper will review the evidence-based treatment of BMS and discuss what we need to do. It is clarified that all referred to BMS in this review are primary BMS according to the definition of ICOP.


From the great advances in the understanding of the etiology and pathogenesis of BMS, it is accepted that BMS is neuropathic pain [4-7]. Chronic anxiety, menopause, neurotoxic agents, and genetic susceptibility such as dopamine D2 receptor polymorphism have all been implicated as causes of BMS [2]. Many studies have indicated that peripheral and central neuropathic mechanisms are involved in the genesis of BMS. Large myelinated Aβ afferent damage in the trigeminal nerve or its brainstem circuits, as well as decreased Aδ fiber signaling with relatively normal C fiber function, are linked to taste changes and ongoing burning pain in BMS [4]. Tongue biopsy revealed that peripheral sensitization was caused by increased expression of nerve growth factor, transient receptor potential vanilloid 1, and P2X3 receptor [2,8-10]. Central neuropathic mechanisms in BMS are associated with hypofunction of the central dopaminergic system in the basal ganglia and decreased endogenous inhibitory control [2,4,11]. Patients of BMS with central neuropathic mechanisms often seem to have associated psychiatric disorders such as depression and anxiety [12,13].


Because BMS is an exclusion diagnosis, a thorough diagnostic procedure is required. Local and systemic factors that can cause a “burning sensation” should be excluded. Local factors include decreased salivary secretion quality and quantity, microtrauma from parafunctional habits, fungal infection, and allergic reactions. Systemic factors are nutritional deficiencies of serum iron, ferritin, zinc, vitamin B12, or folic acid, hormonal changes, diabetes mellitus, thyroid disease, and drugs [2]. Oral examinations, radiography, salivary secretion tests, laboratory tests, psychological, and sleep evaluations will be performed on patients who have intraoral burning symptoms. Electrogustatometry, taste threshold testing with a taste strip, and quantitative sensory testing can all be performed if possible.

It is difficult to differentiate between the peripheral and central neuropathic mechanisms of BMS in individuals in clinical settings. If patients experience immediate pain relief with lingual nerve block anesthesia or a specific topical treatment, it indicates that the patients are most likely affected by the peripheral neuropathic mechanism of BMS [14]. Most patients complain of bilateral symptoms, but, some patients complain of unilateral symptoms. Unilateral symptoms are frequently associated with trauma, such as dental treatment, and are more likely to be caused by a peripheral neuropathic mechanism [15]. If the patients show high scores of anxiety or depression, it means that the patients are more likely to be related to the central neuropathic mechanism of BMS [2].


A complete cure is difficult because BMS is a chronic idiopathic orofacial pain and neuropathic pain. Patients tend to focus on each symptom and cause. Clinicians should concentrate on improving function and daily life rather than on individual symptoms. The ultimate goal of treatment is to reduce the patient's pain so that it does not interfere with daily life, and to eventually improve the patient's quality of life. Pharmacological treatment, cognitive behavioral therapy (CBT), tongue protector, low-level laser therapy (LLLT), and repetitive transcranial magnetic stimulation (rTMS) are the treatment modalities [16]. The treatment for BMS is summarized in Table 1.

1. The importance of Informative Intervention and Reassurance

The first step in the BMS treatment is informative intervention and reassurance. Patients with BMS are likely to believe they have a major problem, so they visit numerous doctors. Pain catastrophizing is defined as a set of exaggerated and negative perceptions and emotions about pain and pain experience [17]. Catastrophizing has three dimensions: rumination (I cannot seem to get it out of my mind), magnification (I wonder if something serious is going to happen), and helplessness (It is awful and feels like it is going to overwhelm me) [17]. Catastrophizing contributes to the aggravation of symptoms and emotional stress, affecting the intensity of pain and how patients cope with pain [18]. BMS patients show high pain catastrophizing scores [19]. A doctor’s reassurance is very important. Reassurance is the removal of fears and concerns about illness [20]. As a result, the oral medicine specialist must provide consistent objective information about BMS, reassure the patient, transform negative thoughts into positive attitudes, and eliminate catastrophizing. Oral medicine specialists should set the goal of treatment and explain this. This procedure could be incorporated into CBT. CBT is a type of psychological treatment that has been shown to be effective for depression, anxiety disorders, chronic pain, and a variety of mental illnesses.

The followings information and reassurances are provided to BMS patients: a chronic pain condition that is relatively common among the elderly; the unknown etiology; explanation about possible mechanisms of BMS development; the reassurance of patients’ anxiety and concerns about the malignant disease; Treatment options, including medications, as well as their reported outcomes and side effects; focusing on maintaining normal functioning, not on symptoms and cause of BMS. After 6 months, the informative intervention and reassurance in BMS treatment reduced pain intensity, pain catastrophizing, and improved quality of life [18]. A case-control study of CBT on BMS showed a significant reduction of pain scores for both short and long-term [21]. Another study found that an “initial approach” of detailed explanation, patient education, instruction on avoiding local irritants, and the use of lubricant reduced the intensity of symptoms in 34% of patients [22]. The information and instructions for BMS patients are shown in Table 2.

2. Pharmacological Treatment

Neuropathic pain medications such as clonazepam, anticonvulsant, tricyclic antidepressant (TCA), serotonin-norepinephrine reuptake inhibitors, and topical capsaicin have been used and studied for the treatment of BMS. Only topical capsaicin and clonazepam were found to be effective in both short- and long-term studies in systematic reviews and meta-analysis [16,23].

The most widely used and studied medication is clonazepam. According to systematic reviews and meta-analyses, clonazepam is effective for symptom remission in patients with BMS in both short-term and long-term applications with topical and systemic administration [16,23,24]. Clonazepam binds to γ-Aminobutyric acid type A (GABAA) receptors and inhibits neuron hyperexcitability in the peripheral and central nervous systems. Peripheral GABAA receptors are abundant in the oral cavity (oral mucosa, mandible, palate, salivary gland, and taste pathway) [25]. The use of topical clonazepam reduced pain more quickly but for a shorter period than systemic clonazepam [26]. When the majority of BMS patients were prescribed clonazepam, 66% of patients showed complete remission or improvement of oral symptoms [22]. Greater initial pain intensity and an irregular pain pattern are predictors of better clonazepam therapeutic efficacy. The presence of depression is a negative predictor of clonazepam therapeutic efficacy [22,27].

Topical capsaicin activates the transient receptor potential vanilloid 1 and desensitizes the peripheral nociceptive C and Aδ fibers. Because topical capsaicin causes initial burning pain, it is recommended that it be used in combination with lidocaine to reduce this pain. One randomized controlled trial reported that capsaicin rinse significantly decreased burning pain [28].

Although the efficacy of alpha lipoic acid, gabapentin, TCA, and SSRIs in BMS treatment has not been demonstrated in a meta-analysis, several studies have reported efficacy [16,29,30].

3. Non-pharmacological Treatment

Non-pharmacological treatments for BMS have included LLLT, rTMS, and tongue protectors. LLLT has an analgesic effect via anti-inflammatory effects and can penetrate tissue deeper, reaching the nerve fibers. In a meta-analysis, LLLT demonstrated a favorable outcome in both short- and long-term assessments [16,31]. rTMS is stimulation of the focal brain cortex via a localized pulsed magnetic field. Dorsal lateral prefrontal cortex (DLPFC) stimulation is used to treat medication-resistant depression as well as acute and chronic pain conditions [32]. A randomized controlled study found that rTMS of the left DLPFC, used in the treatment of depression, reduced pain significantly in BMS patients compared to controls. LLLT and rTMS are non-invasive methods and could be a complement to medication. A randomized controlled study [33] found that using a tongue protector as a shield against trauma or irritation on the tongue reduced pain scores [33]. Tongue protector is a unique device that is beneficial in that it blocks irritation on the tongue, however, it appears difficult to use in general because a tongue protector can be swallowed while being used and cannot be used for an extended period.

Patients with BMS often have anxiety, depression, and sleep disorders as comorbidities. It has been reported that psychological factors such as depression and anxiety play an important role in BMS [34]. If the patients scored high on anxiety or depression, it is strongly advised that they be referred to a psychiatrist for psychiatric intervention.


BMS is difficult to manage and completely cure. As BMS is a chronic pain without obvious causative lesions, it is necessary to focus on the patient’s functions and quality of life rather than the patient’s symptoms. Because the prevalence of spontaneous remission in BMS is low, treatment such as pharmacological or non-pharmacological therapy is required to alleviate discomfort. Objective information and reassurance are very important in treating BMS and should be delivered to the patient. It is critical to comprehend the patient’s symptoms and distress and to never disregard or dismiss symptoms. And the clear goal of treatment should be explained. This process requires a lot of time and doctor’s efforts. We cannot currently request a fee such as a “chronic pain management fee” for CBT in dental clinics. I hope that oral medicine specialists’ efforts and management are reflected in the oral health policies.


No potential conflict of interest relevant to this article was reported.


This study was supported by Wonkwang University in 2022.


The Protocol of BMS treatment

Diagnosis of BMS through BMS treatment

Non-pharmacological intervention Pharmacological intervention
Oral examination
Salivary secretion test
Laboratory test
Taste threshold test
Evaluation of psychological factors and sleep
Informative intervention/reassurance
Cognitive behavioral therapya
Low-level laser therapya
Psychiatric intervention
Topical clonazepama
Systemic clonazepama
Gabapentin 300 mg+ALA 600 mg/day
Nortriptyline 10-30 mg/day
Duloxetine 30-60 mg/day

BMS, burning mouth syndrome; ALA, alpha lipoic acid.

aThe efficacy was demonstrated in a meta-analysis [16,23].

Information and instructions for burning mouth syndrome patients

Burning mouth syndrome (BMS) is a chronic pain condition that has no abnormalities in the oral cavity but has pain and discomfort. It is a kind of neuropathic pain. If you’re diagnosed with BMS, here are the information and instructions to follow.
1. BMS is a chronic painful condition relatively common.
2. The etiology is unknown, but stress, menopause, neurotoxic agent, and genetic susceptibility are reported. The central and peripheral nervous systems are involved in the genesis of BMS.
3. BMS is not an infectious and not a malignant disease.
4. Spontaneous remission is rare. You had better be treated with medications and other modalities.
5. The complete treatment is difficult.
6. Because BMS symptoms do not reduce with only one visit of treatment or medication, it is important not to go visit a doctor here and there and to receive treatment steadily.
7. The medication is a neuropathic pain medication. It acts on the pain mechanisms and calms down the nerve.
8. Do not focus on each symptom and cause.
9. Please focus on maintaining normal function. The ultimate purpose of treatment is to reduce your pain and eventually enhance your quality of life.
  1. International Classification of Orofacial Pain, 1st edition (ICOP). Cephalalgia 2020;40:129-221.
    Pubmed CrossRef
  2. Jääskeläinen SK, Woda A. Burning mouth syndrome. Cephalalgia 2017;37:627-647.
    Pubmed CrossRef
  3. Sardella A, Lodi G, Demarosi F, Bez C, Cassano S, Carrassi A. Burning mouth syndrome: a retrospective study investigating spontaneous remission and response to treatments. Oral Dis 2006;12:152-155.
    Pubmed CrossRef
  4. Jääskeläinen SK. Pathophysiology of primary burning mouth syndrome. Clin Neurophysiol 2012;123:71-77.
    Pubmed CrossRef
  5. Forssell H, Jääskeläinen S, List T, Svensson P, Baad-Hansen L. An update on pathophysiological mechanisms related to idiopathic oro-facial pain conditions with implications for management. J Oral Rehabil 2015;42:300-322.
    Pubmed CrossRef
  6. Carreño-Hernández I, Cassol-Spanemberg J, Rodríguez de Rivera-Campillo E, Estrugo-Devesa A, López-López J. Is burning mouth syndrome a neuropathic pain disorder? A systematic review. J Oral Facial Pain Headache 2021;35:218-229.
    Pubmed CrossRef
  7. Woda A, Dao T, Gremeau-Richard C. Steroid dysregulation and stomatodynia (burning mouth syndrome). J Orofac Pain 2009;23:202-210.
  8. Puhakka A, Forssell H, Soinila S, et al. Peripheral nervous system involvement in primary burning mouth syndrome--results of a pilot study. Oral Dis 2016;22:338-344.
    Pubmed CrossRef
  9. Yilmaz Z, Renton T, Yiangou Y, et al. Burning mouth syndrome as a trigeminal small fibre neuropathy: increased heat and capsaicin receptor TRPV1 in nerve fibres correlates with pain score. J Clin Neurosci 2007;14:864-871.
    Pubmed CrossRef
  10. Beneng K, Yilmaz Z, Yiangou Y, McParland H, Anand P, Renton T. Sensory purinergic receptor P2X3 is elevated in burning mouth syndrome. Int J Oral Maxillofac Surg 2010;39:815-819.
    Pubmed CrossRef
  11. Hagelberg N, Forssell H, Rinne JO, et al. Striatal dopamine D1 and D2 receptors in burning mouth syndrome. Pain 2003;101:149-154.
    Pubmed CrossRef
  12. Taiminen T, Kuusalo L, Lehtinen L, et al. Psychiatric (axis I) and personality (axis II) disorders in patients with burning mouth syndrome or atypical facial pain. Scand J Pain 2011;2:155-160.
    Pubmed CrossRef
  13. Orliaguet M, Misery L. Neuropathic and psychogenic components of burning mouth syndrome: a systematic review. Biomolecules 2021;11:1237.
    Pubmed KoreaMed CrossRef
  14. Grémeau-Richard C, Dubray C, Aublet-Cuvelier B, Ughetto S, Woda A. Effect of lingual nerve block on burning mouth syndrome (stomatodynia): a randomized crossover trial. Pain 2010;149:27-32.
    Pubmed CrossRef
  15. Kim MJ, Kim J, Kho HS. Comparison of clinical characteristics between burning mouth syndrome patients with bilateral and unilateral symptoms. Int J Oral Maxillofac Surg 2020;49:38-43.
    Pubmed CrossRef
  16. Tan HL, Smith JG, Hoffmann J, Renton T. A systematic review of treatment for patients with burning mouth syndrome. Cephalalgia 2022;42:128-161.
    Pubmed KoreaMed CrossRef
  17. Sullivan MJL, Bishop SR, Pivik J. The pain catastrophizing scale: development and validation. Psychol Assess 1995;7:524-532.
  18. Brailo V, Firić M, Vučićević Boras V, Andabak Rogulj A, Krstevski I, Alajbeg I. Impact of reassurance on pain perception in patients with primary burning mouth syndrome. Oral Dis 2016;22:512-516.
    Pubmed CrossRef
  19. Lee GS, Kim HK, Kim ME. Relevance of sleep, pain cognition, and psychological distress with regard to pain in patients with burning mouth syndrome. Cranio 2022;40:79-87.
    Pubmed CrossRef
  20. Traeger AC, Hübscher M, Henschke N, Moseley GL, Lee H, McAuley JH. Effect of primary care-based education on reassurance in patients with acute low back pain: systematic review and meta-analysis. JAMA Intern Med 2015;175:733-743.
    Pubmed CrossRef
  21. Bergdahl J, Anneroth G, Perris H. Cognitive therapy in the treatment of patients with resistant burning mouth syndrome: a controlled study. J Oral Pathol Med 1995;24:213-215.
    Pubmed CrossRef
  22. Kim MJ, Kim J, Kho HS. Treatment outcomes and related clinical characteristics in patients with burning mouth syndrome. Oral Dis 2021;27:1507-1518.
    Pubmed CrossRef
  23. Cui Y, Xu H, Chen FM, et al. Efficacy evaluation of clonazepam for symptom remission in burning mouth syndrome: a meta-analysis. Oral Dis 2016;22:503-511.
    Pubmed CrossRef
  24. McMillan R, Forssell H, Buchanan JA, Glenny AM, Weldon JC, Zakrzewska JM. Interventions for treating burning mouth syndrome. Cochrane Database Syst Rev 2016;11:CD002779.
    Pubmed KoreaMed CrossRef
  25. Tan SN, Song E, Dong XD, Somvanshi RK, Cairns BE. Peripheral GABAA receptor activation modulates rat tongue afferent mechanical sensitivity. Arch Oral Biol 2014;59:251-257.
    Pubmed CrossRef
  26. Rodríguez de Rivera Campillo E, López-López J, Chimenos-Küstner E. Response to topical clonazepam in patients with burning mouth syndrome: a clinical study. Bull Group Int Rech Sci Stomatol Odontol 2010;49:19-29.
  27. Ko JY, Kim MJ, Lee SG, Kho HS. Outcome predictors affecting the efficacy of clonazepam therapy for the management of burning mouth syndrome (BMS). Arch Gerontol Geriatr 2012;55:755-761.
    Pubmed CrossRef
  28. Marino R, Torretta S, Capaccio P, Pignataro L, Spadari F. Different therapeutic strategies for burning mouth syndrome: preliminary data. J Oral Pathol Med 2010;39:611-616.
    Pubmed CrossRef
  29. López-D'alessandro E, Escovich L. Combination of alpha lipoic acid and gabapentin, its efficacy in the treatment of Burning Mouth Syndrome: a randomized, double-blind, placebo controlled trial. Med Oral Patol Oral Cir Bucal 2011;16:e635-e640.
    Pubmed CrossRef
  30. Kim MJ, Kho HS. Treatment outcomes of venlafaxine and duloxetine in refractory burning mouth syndrome patients. J Oral Med Pain 2019;44:83-91.
  31. de Pedro M, López-Pintor RM, Casañas E, Hernández G. Effects of photobiomodulation with low-level laser therapy in burning mouth syndrome: a randomized clinical trial. Oral Dis 2020;26:1764-1776.
    Pubmed CrossRef
  32. Umezaki Y, Badran BW, DeVries WH, Moss J, Gonzales T, George MS. The efficacy of daily prefrontal repetitive transcranial magnetic stimulation (rTMS) for burning mouth syndrome (BMS): a randomized controlled single-blind study. Brain Stimul 2016;9:234-242.
    Pubmed CrossRef
  33. López-Jornet P, Camacho-Alonso F, Andujar-Mateos P. A prospective, randomized study on the efficacy of tongue protector in patients with burning mouth syndrome. Oral Dis 2011;17:277-282.
    Pubmed CrossRef
  34. Galli F, Lodi G, Sardella A, Vegni E. Role of psychological factors in burning mouth syndrome: a systematic review and meta-analysis. Cephalalgia 2017;37:265-277.
    Pubmed CrossRef

March 2024, 49 (1)
Full Text(PDF) Free

Social Network Service

Author ORCID Information